(CRDF) Cardiff Oncology, Inc. Business Model Canvas Research

Cardiff Oncology, Inc. depends on the FDA and site ethics committees for trial starts, protocol amendments, safety reviews, and patient protection. For every oncology program, regulatory alignment is a hard gate, since human studies must clear both IND-level FDA oversight and IRB review at each site.

• FDA approval drives trial access
• IRBs protect patient safety
• Amendments need fast re-review
• Missteps can delay enrollment

Academic oncology centers and key opinion leaders help Cardiff Oncology sharpen trial design, especially for biomarker-led studies in KRAS-mutant colorectal cancer, where about 40% of cases carry KRAS mutations. Their clinical input strengthens combo-regimen choices, supports patient selection in hard-to-treat tumors, and adds credibility with investigators and regulators.

• Shape trial design and endpoints
• Validate biomarker and combo strategy
• Boost trust in complex cancers

Company Name's key work is to track clinical endpoints, adverse events, and translational data in early trials, while biomarker analysis helps pick the right patients and confirm PLK inhibition. This is the proof point for a therapeutic signal before larger studies.

• Measure response and safety together
• Use biomarkers for patient selection
• Validate PLK inhibition mechanism

Cardiff Oncology, Inc. must keep its SEC filings current, defend its patent estate, and rank onvansertib studies by value, because capital is limited and only the strongest indications should move ahead. In 2025, it still had no product revenue, so pipeline discipline is what protects the long-term oncology franchise.

• Keep filings and patent coverage current
• Fund only top-priority indications
• Protect cash by trimming weaker studies

Cardiff Oncology, Inc.’s core intangible asset is its clinical evidence base: trial results, safety datasets, and biomarker readouts from onvansertib studies. These data guide go/no-go choices across indications and combinations, and their value rises as more patients are followed and response patterns get clearer.

One lead asset, onvansertib, means each new dataset can shift pipeline priority fast.

• Trial data reduce clinical risk
• Safety data support dose decisions
• Biomarkers help pick responders

Cardiff Oncology’s scientific team drives study design, biomarker analysis, and development strategy for onvansertib, which is aimed at KRAS-mutant solid tumors. Its patent and know-how base helps validate targets and defend competitive positioning, which matters when future partnering depends on protected data and IP.

• Scientific team guides trial design
• IP supports target validation
• Patent protection aids partnering

Cardiff Oncology, Inc. targets metastatic colorectal cancer, leukemias, and metastatic castration-resistant prostate cancer, three areas with high unmet need and clear demand for clinically meaningful endpoints like progression-free and overall survival. Metastatic colorectal cancer alone causes about 50,000 U.S. deaths each year, underscoring the need for better options.

• High unmet need across three tumor types
• Endpoints tied to real clinical benefit
• Strong trial interest in hard-to-treat disease

Cardiff Oncology's clinical-stage oncology platform is built around multiple active programs, not a single-asset story, so success is less tied to one indication and partnering optionality is broader. That structure also supports pipeline growth, as the Company can advance new oncology shots while keeping development risk spread across programs.

• Multiple programs reduce single-indication risk
• Broader partnering appeal for pharma deals
• Pipeline can expand beyond one lead asset

As a pre-commercial public biotech, Cardiff Oncology, Inc. must keep investors updated on trial milestones, burn rate, and funding needs. These updates are critical because the Company still relies on capital markets, not product sales, to fund development.

• Explains trial progress
• Shows capital use
• Supports financing plans

Partner diligence for Cardiff Oncology, Inc. depends on fast access to clinical evidence, especially from its onvansertib program in metastatic colorectal cancer, including the Phase 2 CRDF-004 study. The company must share clean data packages, protocol updates, and safety readouts so licensing partners can judge risk and value.

That work is not one-off: relationship management has to stay active through each milestone, from 1 study update to the next, because future business development depends on trust, speed, and data quality.

• Share clinical packages early
• Update partners after each readout
• Use diligence to support BD

Cardiff Oncology, Inc. uses publications and conference abstracts to share clinical and translational results, which helps validate the mechanism and build interest with doctors and investors. Peer-reviewed papers and oncology meetings can reach 30,000+ attendees, so this is still a core biotech evidence channel.

• Validates mechanism with published data
• Reaches large oncology audiences fast
• Supports trust before later-stage readouts

Cardiff Oncology, Inc. uses direct business development outreach to pharma and biotech counterparties to open talks on licensing, collaboration, or option deals. This channel matters more as clinical data mature, because better data can improve deal terms and partner interest.

• Direct outreach to pharma and biotech.

• Used for licensing, collaboration, or options.

• Value rises as data mature.

Pharma and biotech partners are a key customer segment for Cardiff Oncology, Inc. because they may want access to its oncology asset onvansertib and the supporting data package for licensing or co-development. With 0 marketed drugs and only one lead clinical asset, partner interest depends most on later-stage efficacy signals from the ongoing program.

• Targets: licensing and collaboration deals
• Value: asset plus clinical data package
• Driver: later-stage efficacy proof

Cardiff Oncology, Inc. is still pre-revenue, so public-market investors are the key funding base that pays for trials before any launch. Their backing depends on clean data readouts, low cash burn, and proof that each step moves the lead asset closer to value.

• Pre-revenue funding source
• Trial milestones drive demand
• Capital discipline matters most

Regulatory, legal, and IP costs sit inside Cardiff Oncology, Inc. development spend because every trial needs FDA filing support, protocol compliance, and patent work. In oncology, where drug patents can make or break value, IP upkeep is a core cost, not a side task.

These expenses protect the pipeline and help keep studies compliant as programs move through 2025/2026 milestones.

• Filing and trial compliance costs
• Patent drafting and maintenance
• Legal defense of key assets

Cardiff Oncology, Inc. carries recurring general and administrative overhead from public-company admin, finance, audit, and investor communications. For a small clinical-stage firm, this spend is meaningful because it supports governance, SEC reporting, and capital raising while revenue is still limited.

• Recurring public-company costs
• Supports governance and financing
• Heavy for a clinical-stage Company

Cardiff Oncology, Inc. can use research and option payments to get cash upfront when partners pay for data access, evaluation rights, or exclusive options before a full license decision. This model helps fund development while keeping upside if a partner later exercises the option.

• Upfront cash reduces dilution risk.
• Partners test data before licensing.
• Option fees can convert to milestones.

Cardiff Oncology, Inc. can use non-dilutive grants and award funding to help pay early R&D before product sales exist. In a clinical-stage model with no product revenue, this stream helps offset cash burn and extend runway.

• Funds early R&D without dilution
• Useful before product sales start
• Lowers pressure on cash runway